8-K: Aprea Therapeutics Reports Promising Early Tumor Shrinkage and Extends Cash Runway into Q2 2026

Aprea Therapeutics announces encouraging early clinical data for its ATR inhibitor, ATRN-119, and WEE1 inhibitor, APR-1051, while extending its cash runway into early Q2 2026.

Summary

• Aprea Therapeutics reported its first quarter 2025 financial results and provided a clinical update on its lead therapeutic candidates.
• Three patients in the ATRN-119 clinical trial demonstrated tumor shrinkage of 7%, 14%, and 21% at a dose level below the recommended Phase 2 dose.
• The ACESOT-1051 trial of the WEE1 inhibitor, APR-1051, continues to advance, with patients now being dosed at 100 mg once daily.
• The company had $19.3 million in cash and cash equivalents as of March 31, 2025, which is expected to fund operations into early Q2 2026.
• The company reported an operating loss of $4.1 million for the first quarter ended March 31, 2025, compared to an operating loss of $3.1 million in the first quarter of 2024.
• Research and Development (R&D) expenses were $2.5 million for the quarter ended March 31, 2025, compared to $1.6 million for the first quarter of 2024.
• General and Administrative (G&A) expenses were $1.8 million for the quarter ended March 31, 2025, compared to $1.9 million for the first quarter of 2024.
• The Company reported a net loss of $3.9 million ($0.66 per basic share) on approximately 6.0 million weighted-average common shares outstanding for the quarter ended March 31, 2025, compared to a net loss of $2.8 million ($0.67 per basic share) on approximately 4.2 million weighted average common shares outstanding for the comparable period in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to encouraging early clinical data and a sufficient cash runway, but the increased operating loss and inherent risks of drug development temper the overall sentiment.

Positives

• ATRN-119 demonstrated tumor shrinkage in some patients, indicating potential anti-tumor activity.
• APR-1051 is advancing in clinical trials with an encouraging tolerability profile, allowing for accelerated dose escalation.
• The company's cash position is sufficient to fund operations into early Q2 2026.
• The Material Transfer Agreement with MD Anderson Cancer Center could lead to valuable preclinical data supporting future clinical trials for APR-1051.
• Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations.

Negatives

• The company reported an operating loss of $4.1 million for the first quarter of 2025, which is higher than the $3.1 million loss in the first quarter of 2024.
• The company is still in the early stages of clinical development, and there is no guarantee that its product candidates will be successful.
• The company has a limited cash runway and may need to raise additional capital in the future.

Risks

• The success, timing, and cost of ongoing and anticipated clinical trials are subject to risks and uncertainties.
• The company's ability to continue as a going concern is dependent on securing additional funding.
• Preliminary results from clinical trials are not necessarily indicative of final results.
• The company's understanding of product candidates' mechanisms of action and interpretation of preclinical and early clinical results may be inaccurate.

Future Outlook

The company anticipates reporting preliminary efficacy data for APR-1051 in the second half of 2025 and expects to identify the RP2D for ATRN-119 in the first half of 2026. Aprea believes its current cash and cash equivalents will be sufficient to fund operations into early Q2 2026.

Management Comments

• 2025 is off to a strong start with significant clinical progress across both of our lead therapeutic candidates, said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea.
• In our ongoing ATRN-119 clinical program, three patients in the latest twice daily cohort demonstrated stable disease, with tumor shrinkage of 7%, 14% and 21%, marking early evidence of single agent, anti-tumor activity.
• At Aprea, we aim to redefine what is possible for patients with limited treatment options and we see ATRN-119 and APR-1051 as important clinical assets that may help us achieve this goal.

Industry Context

Aprea is focused on developing therapies that exploit cancer cell vulnerabilities, a growing area of interest in the biopharmaceutical industry. The company's ATR and WEE1 inhibitors target the DNA Damage Response (DDR) pathway, which is crucial for cancer cell survival. Success in this area could position Aprea as a leader in precision oncology.

Comparison to Industry Standards

• AstraZeneca discontinued development of AZD-1775 due to its tolerability profile, highlighting the challenges in developing WEE1 inhibitors.
• Multiple Phase 2 studies with Adavosertib, another WEE1 inhibitor, have shown substantial single-agent activity, but also significant Grade 3 hematological, GI, and CV toxicities.
• Aprea's APR-1051 is designed to potentially solve tolerability challenges of the WEE1 class and may achieve greater clinical activity than other programs currently in development.
• Other ATR inhibitors, such as AZD6738 (AstraZeneca), BAY1895344 (Bayer), and RP-3500 (Repare), have reported challenges with hematological toxicities and require intermittent dosing schedules.
• Aprea's ATRN-119 is a macrocyclic ATR inhibitor, potentially differentiated from other ATR inhibitors in selectivity and toxicity profile, and allows for continuous dosing.

Stakeholder Impact

• Shareholders may react positively to the encouraging clinical data and extended cash runway.
• Employees may be motivated by the progress of the company's clinical programs.
• Patients with advanced solid tumors may benefit from the development of new treatment options.
• The company's suppliers and creditors may be reassured by its financial stability.

Next Steps

• Aprea intends to submit an abstract to a major oncology conference.
• The company will continue dose escalation in the ACESOT-1051 trial, with the next cohort expected to be dosed at 150 mg.
• Future cohorts in the ABOYA-119 trial may evaluate intermittent dosing schedules to further refine and optimize therapeutic efficacy and tolerability.

Key Dates

Keywords

ATRN-119, APR-1051, ATR inhibitor, WEE1 inhibitor, clinical trials, cancer, Aprea Therapeutics, oncology, DDR, tumor shrinkage